Suppr超能文献

CK5/6、p63、GATA6 和 HNF4a 的联合免疫组化预测治疗初治胰腺导管腺癌的临床结局。

Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma.

机构信息

Department of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.

Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.

出版信息

Sci Rep. 2024 Jul 6;14(1):15598. doi: 10.1038/s41598-024-65900-w.

Abstract

Although sequence-based studies show that basal-like features lead to worse prognosis and chemotherapy-resistance compared to the classical subtype in advanced pancreatic ductal adenocarcinoma (PDAC), a surrogate biomarker distinguishing between these subtypes in routine diagnostic practice remains to be identified. We aimed to evaluate the utility of immunohistochemistry (IHC) expression subtypes generated by unsupervised hierarchical clustering based on staining scores of four markers (CK5/6, p63, GATA6, HNF4a) applied to endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNAB) materials. EUS-FNAB materials taken from 190 treatment-naïve advanced PDAC patients were analyzed, and three IHC patterns were established (Classical, Transitional, and Basal-like pattern). Basal-like pattern (high co-expression of CK5/6 and p63 with low expression of GATA6 and HNF4a) was significantly associated with squamous differentiation histology (p < 0.001) and demonstrated the worst overall survival among our cohort (p = 0.004). IHC expression subtype (Transitional, Basal vs Classical) was an independent poor prognosticator in multivariate analysis [HR 1.58 (95% CI 1.01-2.38), p = 0.047]. Furthermore, CK5/6 expression was an independent poor prognostic factor in histological glandular type PDAC [HR 2.82 (95% CI 1.31-6.08), p = 0.008]. Our results suggest that IHC expression patterns successfully predict molecular features indicative of the Basal-like subgroup in advanced PDAC. These results provide the basis for appropriate stratification for therapeutic selection and prognostic estimation of advanced PDAC in a simplified manner.

摘要

虽然基于序列的研究表明,与经典亚型相比,基底样特征导致晚期胰腺导管腺癌(PDAC)的预后更差且对化疗耐药,但在常规诊断实践中仍需要确定区分这些亚型的替代生物标志物。我们旨在评估基于四个标志物(CK5/6、p63、GATA6、HNF4a)染色评分的无监督层次聚类生成的免疫组织化学(IHC)表达亚型在经内镜超声引导细针抽吸活检(EUS-FNAB)材料中的应用价值。分析了 190 名未经治疗的晚期 PDAC 患者的 EUS-FNAB 材料,并建立了三种 IHC 模式(经典型、过渡型和基底样型)。基底样型(CK5/6 和 p63 高表达,GATA6 和 HNF4a 低表达)与鳞状分化组织学显著相关(p<0.001),并且在我们的队列中总生存最差(p=0.004)。在多变量分析中,IHC 表达亚型(过渡型、基底样型与经典型)是独立的预后不良因素[HR 1.58(95%CI 1.01-2.38),p=0.047]。此外,CK5/6 表达在组织学腺型 PDAC 中是独立的预后不良因素[HR 2.82(95%CI 1.31-6.08),p=0.008]。我们的结果表明,IHC 表达模式成功预测了晚期 PDAC 中基底样亚组的分子特征。这些结果为晚期 PDAC 的治疗选择和预后评估提供了简化的分层依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3013/11227498/755f97a9d25c/41598_2024_65900_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验